Publications by authors named "Carol Agudelo Rico"
Article Synopsis
- The narrative review aims to enhance understanding of hemophilia A, a genetic disease that significantly affects the quality of life and is costly for health systems, particularly noted as one of the top economic burdens in Colombia.
- The review highlights the shift towards precision medicine in treating hemophilia, emphasizing the importance of genetic, pharmacokinetic, and environmental factors that affect treatment efficacy.
- Building robust scientific evidence with strong statistical backing is essential to personalize treatment approaches in a cost-effective manner.
Article Synopsis
- * The study included 12 patients with severe hemophilia A, aged 6 to 48, and found that 50% had an inversion of intron 22, which is associated with a higher risk of developing inhibitors.
- * Results showed that 83.3% of patients had null mutations, with 66.7% presenting high inhibitor titers, suggesting a need for further research on how these mutations impact treatment effectiveness and coagulation factors.
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program.
Samuel Sarmiento Doncel Gina Alejandra Diaz Mosquera Javier Mauricio Cortes Nelson Ramirez Plazas Francisco Javier Meza Carol Agudelo Rico
Hematol Rep
November 2021
In recent decades, hemophilia A treatment has been focused on body weight, without taking pharmacokinetic parameters into account. Previous research has shown that the individual pharmacokinetic response is more effective in predicting the required dose of clotting factor. We want to evaluate the impact on reducing the frequency of bleeding in patients treated with recombinant factor VIII, based on a personalized comprehensive management program.
View Article and Find Full Text PDF